Stada Arzneimittel AG is beefing up its presence in Russia and the Commonwealth of Independent States (CIS) by snapping up a portfolio of OTC and prescription brands from Japan’s Takeda Pharmaceutical Co. Ltd. for $660m.
Stada Grows In Russia And CIS With Takeda Brands
Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
More from Deals
• By
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
• By
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
• By
Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.
• By
Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.
More from Business
• By
CHPA Health In Hand Foundation accepting nominations for 2025 US Self-Care Marketing Awards; Celsius hires former PepsiCo as president/COO and closes $1.8bn acquisition of energy drink competitor Alani; and AdvoCare adds John Peirano as integrated marketing VP after hiring Kathy Blosser supply chain VP.
• By
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
• By
Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”